Intensive chemotherapy in patients with lymphoma: Management of the risk of hyperuricemia

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 93-104

  Tarella, Corrado ^a   Bono, Davide ^a   Zanni, Manuela ^a   Ricca, Irene ^a   Caracciolo, Daniele ^a  

^a Divisione Universitaria di Ematologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AUTOTRANSPLANTATION; DRUG EFFECT; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY; LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; REVIEW; RISK; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; HYPERURICEMIA; KIDNEY; LYMPHOMA; MALE; MIDDLE AGED; RISK; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 16644374440     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (42)

1. Salles G, Coiffier B: Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol 1999;12:151-169.
2. Goldstone AH, McMillan AK: The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 1993;4:21-27.
3. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
4. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed Hodgkin's disease: Results of a BNLI randomised trial. The Lancet 1993;341:1051-1054.
5. Laport GF, Williams SF: The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1998;25:502-517.
6. Shipp MA, Abeloff MD, Antman KH, et al: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 1999;17:423-429.
7. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257-3262.
8. Tarella C, Caracciolo D, Corradini P, et al: Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000;14:740-747.
9. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1295.
10. Haioun C, Lepage L, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87 - 2 protocol - a groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 2000;18:3025-3030.
11. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 1989;ii:580-585.
12. Tarella C, Gavarotti P, Caracciolo D, et al: Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Ann Oncol 1995;6(suppl 4):S3-S8.
13. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-357.
14. Hartmann O, Le Corroller AG, Blaise D, et al: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphoma: Hematologic recovery and cost. Ann Intern Med 1997;126:600-607.
15. Tarella C, Zallio F, Caracciolo D, et al: High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: High tolerability with reversible cardiotoxicity. Leukemia 2001;15:256-263.
16. Vitolo U, Cortellazzo S, Liberati AM, et al: Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997;15:491-498.
17. Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796-2802.
18. Bosly A, Sonnet A, Salles G, et al: Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA:LNH RP 93. Blood 1997;90(suppl 1):S594.
19. Moskowitz CH, Nimer SD, Zelenetz AD, et al: A 2-step comprehensive high-dose chemotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
20. Tarella C, Cuttica A, Vitolo U, et al: High-dose sequential chemotherapy and peripheral blood progenitor cell (PBPC) autografting in refractory/relapsed Hodgkin's lymphoma: A multicenter study of The Intergruppo Italiano Linfomi (Iil) showing prolonged disease-free survival in Patients treated at first relapse. Cancer 2003;97:2748-2759.
21. Gianni AM, Bregni M, Siena S, et al: Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol 1989;7:139-148.
22. Tarella C, Cuttica A, Caracciolo D, et al: High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: Long-term analysis and future developments. Ann Hematol 2001;80(suppl 3):B123-B126.
23. Caracciolo D, Gavarotti P, Aglietta M, et al: High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1993;12:621-625.
24. Cuttica A, Zallio F, Ladetto M, et al: Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: Evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer 2003;98:983-992.
25. Corradini P, Ladetto M, Pileri A, Tarella C: Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies. Leukemia 1999;13:1691-1695.
26. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high dose chemotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-2534.
27. Stone RM, Neuberg D, Soiffer R, et al: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2535-2542.
28. Grossbard ML, Nadler LM: Monoclonal antibody therapy for indolent lymphomas. Semin Oncol 1993;20(suppl 5):118.
29. Coiffier B, Lepage E, Brière J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235.
30. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 2000;96:864-869.
31. Ladetto M, Zallio F, Vallet S, et al: Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001;15:1941-1949.
32. Zager RA, O'Quigley J, Zager BK, et al: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989;13:210-216.
33. Apperley JF, Gluckman E, Gratwohl A (eds): The EBMT Handbook - Blood and Marrow Transplantation. 2000, chap 7, pp 97-109.
34. Altman A: Acute tumor lysis syndrome. Semin Oncol 2000;28(suppl 2):3-8.
35. Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94:133-139.
36. Sparano J, Ramirez M, Wiernik PH: Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 1990;65:1072-1073.
37. Passas AB, Desikan KR, Siegel D, et al: Tumor lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999;105:938-941.
38. Wetzstein GA: Tumor Lysis Syndrome: A Treatment Guide. New York, NY, McMahon Publishers Group, 2000.
39. Pui C-H, Mahmoud HH, Wiley JM, et al: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
40. Goldman SC, Holcenberg S, Finklestein Z, et al: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
41. Cortelazzo S, Rambaldi A, Rossi A, et al: Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001;114:333-341.
42. Corradini P, Ladetto M, Zallio F, et al: Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission can be frequently attained only in follicular subtypes. J Clin Oncol 2004;22:1460-1468.